Loading...
•
Dec 31, 2023
Tarsus Q4 2023 Earnings Report
Reported strong fourth quarter results driven by XDEMVY net product sales and pipeline advancements.
Key Takeaways
Tarsus Pharmaceuticals reported strong Q4 2023 financial results, driven by $13.1 million in revenues from XDEMVY net product sales. The company also highlighted the positive progress of its clinical pipeline and commercial initiatives.
Generated $13.1 million in revenue in Q4 2023, driven by XDEMVY net product sales.
Reported positive topline results from the Phase 2a Galatea trial evaluating TP-04 for Papulopustular Rosacea (PPR).
Advanced pipeline with positive proof-of-concept results across entire clinical portfolio.
Delivered more than 17,400 bottles of XDEMVY to patients.
Tarsus
Tarsus
Forward Guidance
Tarsus anticipates an impactful year ahead, driven by the approval, launch, and rapid uptake of XDEMVY.